The Association Between Serum Calcium Levels and Short-Term Mortality in Patients with Chronic Heart Failure

Anne-Sofie Caroline Jensen1, Christoffer Polcwiartek2, Peter Søgaard3

  • 1Department of Cardiology, Aalborg University Hospital, Denmark.

Insights

Altered calcium levels in chronic heart failure patients significantly increase mortality risk. Hypocalcemia and hypercalcemia are linked to higher short-term and long-term death rates, indicating a poor prognosis.

Area of Science:

  • Cardiology
  • Endocrinology
  • Clinical Research

Background:

  • Chronic heart failure (CHF) patients exhibit vulnerable myocardial function and are prone to electrolyte disturbances.
  • Diuretic use in CHF is common but can exacerbate electrolyte imbalances.
  • Calcium homeostasis alterations may impact mortality risk in CHF.

Purpose of the Study:

  • To investigate the association between altered calcium homeostasis and all-cause mortality in patients with chronic heart failure.
  • To determine the specific risks associated with hypocalcemia and hypercalcemia in CHF.

Main Methods:

  • Utilized Danish national registries to identify CHF patients meeting specific treatment criteria.
  • Categorized patients into hypocalcemia (<1.18 mmol/L), normocalcemia (1.18-1.32 mmol/L), and hypercalcemia (>1.32 mmol/L) groups.
  • Employed Cox regression analysis to assess mortality risk, calculating hazard ratios (HRs) and 95% confidence intervals (CIs).

Main Results:

  • 32.6% of 2729 CHF patients had hypocalcemia, 63.1% normocalcemia, and 4.3% hypercalcemia.
  • Hypocalcemia showed increased mortality risk: HR 2.22 (≤30 days) and HR 1.52 (>30 days).
  • Hypercalcemia also showed increased mortality risk: HR 1.67 (≤30 days) and HR 1.87 (>30 days).

Conclusions:

  • Altered calcium homeostasis, both hypocalcemia and hypercalcemia, is significantly associated with increased short-term and long-term mortality in chronic heart failure patients.
  • Nearly one-third of CHF patients experienced hypocalcemia, correlating with a poor prognosis.
  • Monitoring and managing calcium levels in CHF patients may be crucial for improving outcomes.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
894
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
865
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
329
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
305